Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Teva Canada Announces Sale of Mirabel (Quebec) Facility to Halo Pharmaceutical

Published: Thursday, April 05, 2012
Last Updated: Thursday, April 05, 2012
Bookmark and Share
Jobs and manufacturing capacity to remain in Quebec.

Teva Canada has announced that it has finalized an agreement under which Halo Pharmaceutical, a contract manufacturing organization (CMO), will acquire Teva's Mirabel (Quebec) manufacturing facility.

The transaction is subject to approval by the Competition Bureau, successful negotiation of manufacturing agreements between Teva Canada and Halo and receipt of manufacturing permits from various authorities. The closing of this transaction is currently scheduled for June 30, 2012.

"We are extremely pleased that our continued efforts to secure a buyer have been successful, not only for Teva, but most importantly for our dedicated Mirabel employees, Canadian consumers and the province of Quebec", said Barry Fishman, President & CEO of Teva Canada Limited.

Fishman continued, "We believe Halo Pharmaceutical is a highly qualified contract manufacturer who will maintain a manufacturing presence in Quebec."

"Halo Pharmaceutical is delighted to become a supplier of quality products to Teva Canada", observed Clive Bennett, President and CEO, Halo Pharmaceutical.

Bennett continued. "Through this strategically important acquisition we gain a pool of skilled people with wide ranging experience, the opportunity to provide continuing employment to many present employees and to grow our global business."

Through Teva's sale to Halo, approximately 150 employees will continue to be employed at Mirabel.

Halo plans to grow commercial contract manufacturing, and product development through the Mirabel facility, helping to sustain local employment in an important pharmaceutical segment.

While the Mirabel plant will continue to support many products for the Canadian market, this addition to Halo's manufacturing network will also allow production to be exported outside of Canada.

"With the acquisition of this state-of-the art facility, Halo's market reach will expand to Europe in addition to the US and Canadian markets", added Mohd Asif, CFO, Halo Pharmaceutical. "Furthermore, Halo will be able to offer new distribution capabilities to its customers as well as unique R&D services."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Teva Canada Completes Sale of Mirabel Facility to Halo Pharmaceutical
Canadian production capacity & jobs maintained.
Tuesday, August 07, 2012
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!